Symbiotec Pharmalab Ltd. IPO

The pharmaceutical market is experiencing tandem growth in both small-molecule drugs and biologics. While small molecules remain dominant with a 64.8% share in 2025 due to their broad therapeutic use and cost-effectiveness, the biologics segment is witnessing faster expansion, with a projected ... growth rate of 8.7% between 2025 and 2030 due to their higher efficacy and safety, along with their ability to target complex, previously untreatable conditions. The global pharmaceutical market continues to exhibit strong momentum across both biologics and small molecule drugs, with each modality contributing distinctly to overall market expansion. Small molecules remain the dominant segment, accounting for 64.8% of the global market by value in 2025. Their continuing relevance is anchored in widespread clinical usage, affordability, ease of administration, and scalable manufacturing. Despite a slower growth rate of 3.8% (2020–2025) and a projected 5.0% CAGR (2025–2030), small molecules continue to drive high prescription volumes and dominate Food and Drug Administration (FDA) new drug approvals, with 67% of the Center for Drug Evaluation and Research’s (CDER) approvals in 20257 attributed to this class. They also account for 55% of the global R&D pipeline and remain essential for expanding access in price-sensitive and infrastructure-constrained markets. Meanwhile, biologics, including biosimilars, are rapidly gaining ground and are expected to expand significantly, representing 28.2% market share in 2020, which is expected to increase to 39.2% by 2030, with revenues increasing from USD 341.2 billion in 2020 to a projected USD 865.0 billion in 2030. This sustained growth of 8.7% CAGR from 2025 to 2030 is driven by scientific breakthroughs in antibody therapeutics, gene and cell therapies, and immunooncology. Biologics has transformed care for complex diseases such as cancer, autoimmune disorders, and rare genetic conditions, by offering high specificity and superior efficacy. Despite longer development timelines and more complex manufacturing, biologics enjoy blockbuster potential. In 2025, based on revenues, 12 of the top 15 selling medications were biologics. Among biologics, recombinant antibodies and protein and peptides have dominated the market, contributing to 60.6% of biologics revenue in 2025. However, the next generation of biologics, particularly cell and gene therapies and antibody drug conjugates (ADCs), will drive exponential growth with forecasted CAGR ranging between 25-28% between 2025 and 2030. With continued innovation, growing biosimilar adoption, and growing demand for targeted therapies, biologics are set to remain a key engine of pharmaceutical growth. Read more